Vaccine for glioblastoma after standard treatment
Part of Cancer clinical trials.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with glioblastoma and already completed radiation therapy with temozolomide.
- You must be in fairly good health, able to care for yourself (Karnofsky score of 60% or higher).
- For the first part of the study, your tumor must have a specific marker called HLA-A2 and express a protein called PTPRZ1.
- You must have tumor tissue available for additional testing.
- You must not be taking high doses of steroids (more than 10 mg of prednisone daily).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
This trial tests adding a vaccine (UCPVax) with or without the immunotherapy drug pembrolizumab to standard chemotherapy after initial treatment. The goal is to see if these extra treatments can help prevent the brain tumor from coming back.
This trial is testing a new vaccine (Bvax) added to the usual chemotherapy and radiation for glioblastoma. It aims to train your immune system to fight the tumor and possibly improve outcomes.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
Hear when a new Newly Diagnosed Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.